CHMP agrees Revlimid, Tresiba, Velcade and Xiapex extensions
This article was originally published in Scrip
Executive Summary
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) made four positive recommendations on extensions of therapeutic indications at its December meeting. The lucky products were Celgene's Revlimid (lenalidomide), Novo Nordisk's Tresiba (insulin degludec), Janssen-Cilag's Velcade (bortezomib) and Swedish Orphan Biovitrum's Xiapex (collagenase clostridium histolyticum).